This message contains images. If you don't see images, click here to view.
Advertise in this news brief.

Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           March 18, 2015

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store


What patients prefer to know
The New York Times
Rachel A. Freedman, an oncologist who specializes in breast cancer at the Dana Farber Cancer Institute in Boston, said she noticed a few years ago that many patients who were referred to her had little understanding of their disease or its treatment. There was hardly any published information on what patients knew about their own cancers, so Dr. Freedman and some colleagues decided to conduct a study. They asked 500 women four questions: Did they know the stage of their tumor, the grade (an indicator of how aggressive a cancer is), and whether it was fed by estrogen or a growth factor called HER-2?
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Special Interest Session VI: SGO Latin America Symposium — March 30
Learn about relevant topics in gynecologic oncology in Latin America and options for collaboration during Special Interest Session VI: SGO Latin America Symposium – The Current, Present & Future of Gynecologic Oncology in Developing Countries-A Call for Future Partnerships on Monday, March 30, from 4:00 p.m. to 7:00 p.m. at the Hilton Chicago during the SGO Annual Meeting.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Medicare announces new ACO program
MedPage Today
Centers for Medicare and Medicaid Services (CMS) is launching a "Next Generation" accountable care organization (ACO) program that the agency hopes will be more attractive to Medicare providers, a CMS official said recently. When CMS launched its Pioneer and Shared Savings ACO programs, "we started to hear from stakeholders that [said], 'You really need a next-generation model,'" explained CMS chief medical officer Patrick Conway, MD, during a webinar sponsored by the Association of Health Care Journalists. The new model "offers more predictable financial targets and enables providers and beneficiaries great opportunities to coordinate care."
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.

Skyrocketing cancer drug costs 'are damaging patient care'
Medical News Today
Dr. S. Vincent Rajkumar, of Mayo Clinic Cancer Center in Rochester, MN, and his colleague Hagop Kantarjian, of The University of Texas MD Anderson Cancer Center in Houston, report that the average price of cancer drugs was $5,000 to $10,000 for 1 year of treatment before 2000. By 2012, however, the cost of drugs for 1 year of treatment had rocketed to more than $100,000. Over the same period, note the authors, the average household income in the US fell by about 8 percent.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Challenges in the treatment of ovarian and endometrial cancers
OncLive (Q&A)
All gynecological cancers are poorly understood, but the lack of knowledge about ovarian and endometria have the biggest impact on women, says Sanaz Memarzadeh, MD, PhD, associate professor of obstetrics and gynecology at UCLA.. OncLive spoke with Dr. Memarzadeh on why these two gynecological subtypes are so challenging to treat and what future research is needed to further understand these diseases.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Intraperitoneal chemotherapy in ovarian cancer (overview)
OncLive (Video interview)
Long-term findings from two randomized trials demonstrated that intraperitoneal (IP) chemotherapy significantly improved survival compared with intravenous (IV) therapy. The combined analysis of the GOG-172 and GOG-114 trials showed that patients treated with IP chemotherapy experienced a 16% reduction in the risk of progression compared with IV therapy. Additionally, IP chemotherapy led to a median overall survival (OS) of 62 months compared with 51 months for IV therapy. This video interview features Michael J. Birrer, MD, PhD, Robert A. Burger, MD, Warner K. Huh, MD, and James Tate Thigpen, MD.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Uncover Hereditary Cancer Risk for Your Patients
The average OB/GYN has 400 patients who meet criteria for further evaluation of hereditary cancer syndrome. Learn how to identify high-risk patients.
Advertise here!

To find out how to feature your company in the SGO News Brief and other advertising opportunities, Contact Geoffrey Forneret at 469-420-2629.


2 out of 3 people live at least 5 years after a cancer diagnosis
U.S. News & World Report
Improvements in the way cancer is identified and treated has resulted in more Americans surviving with the disease, shows a new study from the Centers for Disease Control and Prevention. Now, 2 out of 3 people who have cancer survive five years or more. Cervical cancer rates also are outlined in the report, though it is too early to determine whether the HPV vaccines have had an effect, said Rebecca Siegel, director of surveillance information for the American Cancer Society. The HPV test and PAP smears, however, have helped with early detection.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Correlated spectroscopy pinpoints changes in BRCA1/2 carriers
Oncology Nurse Advisor
Use of localized correlated spectroscopy (COSY) shows significant changes in women with BRCA1 and BRCA2 mutations, according to a study published online March 3 in Radiology. Saadallah Ramadan, PhD, from the University of Newcastle in Australia, and colleagues compared localized COSY images recorded at 3 Tesla in the breast tissue of women carrying BRCA1 (nine women) or BRCA2 (14 women) gene mutations and in 10 healthy controls with no family history of breast cancer. Participants also underwent contrast material-enhanced magnetic resonance imaging (MRI) and ultrasonography.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Visit the SGO Women's Cancer News archive page.

Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news

Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

March 11, 2015
March 4, 2015
Feb. 25, 2015
Feb. 18, 2015

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063